# An Open Label Extension Study of the Efficacy of MORAb-003

> **NCT01018563** · PHASE2 · TERMINATED · sponsor: **Morphotek** · enrollment: 3 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** MORAb-003

## Key facts

- **NCT ID:** NCT01018563
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01-13
- **Primary completion:** 2013-03-05
- **Final completion:** 2013-03-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study was terminated by sponsor due to futile results in NCT00849667 study.
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018563, "An Open Label Extension Study of the Efficacy of MORAb-003". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01018563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*